Venous Thromboembolism Prophylaxis in the Medical Patient: Controversies and Perspectives

American Journal of Medicine

Volumn 122, Issue 12, 2009, Pages 1077-1084

  Spyropoulos, Alex C ^a   Mahan, Charles ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b LOVELACE MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Fondaparinux; Heparin; Low molecular weight heparin; Pulmonary embolism; Thrombosis; Venous thromboembolism

Indexed keywords

DALTEPARIN; ENOXAPARIN; ESTROGEN DERIVATIVE; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TINZAPARIN;

BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; INCIDENCE; KIDNEY FAILURE; LUNG EMBOLISM; MORBIDITY; MORTALITY; OBESITY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; UNITED STATES; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; HEPARIN; HOSPITALIZATION; HUMANS; OBESITY; RENAL INSUFFICIENCY; RISK FACTORS; STOCKINGS, COMPRESSION; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 72049130819     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.04.027     Document Type: Review

References (44)

1. Geerts W.H., Pineo G.F., Heit J., et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 Suppl (2004) 338S-400S
2. Anderson Jr. F.A., Wheeler H.B., Goldberg R.J., et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester Deep Vein Thrombosis Study. Arch Intern Med 151 (1991) 933-938
3. Heit J.A., Cohen A.T., Anderson Jr. F.A., et al. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (venous thromboembolism) in the US. [abstract]. Blood 106 (2005) Abstract 910
4. Anderson Jr. F.A., and Spencer F.A. Risk factors for venous thromboembolism. Circulation 107 (2003) I9-I16
5. Cohen A.T., Tapson V.F., Bergmann J.-F., et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371 (2008) 387-394
6. Spyropoulos A.C., and Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 13 (2007) 475-486
7. Piazza G., Seddighzadeh A., and Goldhaber S.Z. Double trouble for 2,609 hospitalized medical patients who developed deep vein thrombosis: prophylaxis omitted more often and pulmonary embolism more frequent. Chest 132 (2007) 554-561
8. Cohen A.T., Edmondson R.A., Phillips R.A., et al. The changing pattern of venous thromboembolic disease. Haemostasis 26 (1996) 65-71
9. Cohen A.T., Davidson B.L., Gallus A.S., et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332 (2006) 325-329
10. Tapson V.F., Decousus H., Pini M., et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 132 (2007) 936-945
11. Goldhaber S.Z., Tapson V.F., and DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 93 (2004) 259-262
12. Amin A., Stemkowski S., Lin J., et al. Thromboprophylaxis rates in US medical centers: success or failure?. J Thromb Haemost 5 (2007) 1610-1616
13. Nicolaides A.N., Fareed J., Kakkar A.K., et al. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 25 (2006) 101-161
14. Limpus A., Chaboyer W., McDonald E., et al. Mechanical thromboprophylaxis in critically ill patients: a systematic review and meta-analysis. Am J Crit Care 15 (2006) 402-412
15. Lacut K., Bressollette L., Le Gal G., et al., VICTORIAh (Venous Intermittent Compression and Thrombosis Occurrence Related to Intra-cerebral Acute hemorrhage) Investigators. Prevention of venous thrombosis in patients with acute intracerebral hemorrhage. Neurology 65 (2005) 865-869
16. Geerts W.H., Bergqvist D., Pineo G.F., et al., American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 6 Suppl (2008) 381S-453S
17. Samama M.M., Cohen A.T., Darmon J.Y., et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 341 (1999) 793-800
18. Leizorovicz A., Cohen A.T., Turpie A.G., et al. Randomized placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110 (2004) 874-879
19. Dentali F., Douketis J.D., Gianni M., et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 146 (2007) 278-288
20. King C.S., Holley A.B., Jackson J.L., et al. Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: a metaanalysis. Chest 131 (2007) 507-516
21. Spyropoulos A.C. Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patients. Chest 128 (2005) 958-969
22. Wein L., Wein S., Haas S.J., et al. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. Arch Intern Med 167 (2007) 1476-1486
23. Sherman D.G., Albers G.W., Bladin C., et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet 369 (2007) 1347-1355
24. Kleber F.X., Witt C., Vogel G., et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 145 (2003) 614-621
25. Lechler E., Schramm W., Flosbach C.W., et al. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). Haemostasis 26 Suppl 2 (1996) 49-56
26. Alikhan R., and Cohen A.T. A safety analysis of thromboprophylaxis in acute medical illness. Thromb Haemost 89 (2003) 590-591
27. McGarry L.J., Stokes M.E., and Thompson D. Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients. Thromb J 4 (2006) 17-25
28. Mismetti P., Laporte-Simitsidis S., Tardy B., et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 83 (2000) 14-19
29. Shorr A.F., Jackson W.L., Sherner J.H., et al. Differences between low-molecular weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis. Chest 133 (2008) 149-155
30. Edelsberg J., Hagiwara M., Taneja C., et al. Risk of venous thromboembolism among hospitalized medically ill patients. Am J Health Syst Pharm 63 Suppl 6 (2006) S16-S22
31. Spencer F., Lessard D., Emery C., et al. Venous thromboembolism in the outpatient setting. Arch Intern Med 167 (2007) 1471-1475
32. Hull R.D., Schellong S.M., Tapson V.F., et al. Extended-duration venous thromboembolism (venous thromboembolism) prophylaxis in acutely ill medical patients with recent reduced morbidity: the EXCLAIM study. [abstract]. J Thromb Haemost 5 Suppl 2 (2007) O-S-001
33. Kucher N., Leizorovicz A., Vaitkus P.T., et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med 165 (2005) 341-345
34. Lim W., Dentali F., Eikelboom J.W., et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144 (2006) 673-684
35. Rabbat C.G., Cook D.J., Crowther M.A., et al. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J Crit Care 20 (2005) 357-363
36. Tincani E., Mannucci C., Casolari B., et al. Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica 91 (2006) 976-979
37. et al. Douketis J., Cook D., Canadian Critical Care Trials Group. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med 168 (2008) 1805-1812
38. Mahé I., Aghassarian M., Drouet L., et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 97 (2007) 581-586
39. Hirsh J., and Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 188S-203S
40. Lim W., Cook D.J., and Crowther M.A. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol 15 (2004) 3192-3206
41. Venous thromboembolic event prophylaxis in medically ill patients. Clinicaltrials.gov web site. http://www.clinicaltrials.gov/ct2/show/NCT00571649?term=rivaroxaban&rank=9 Accessed October 31, 2008
42. Study of apixaban for the prevention of thrombosis-related events in patients with acute medical illness. Clinicaltrials.gov web site. http://clinicaltrials.gov/show/NCT00457002 Accessed November 7, 2008
43. The Joint Commission. The 2008 National Patient Safety Goals Manual Chapter. http://www.jointcommission.org/NR/rdonlyres/A391E808-AF10-4C5E-873D-CB185E2009F0/0/08_AHC_NPSGs_Master.pdf Accessed November 10, 2008
44. The Joint Commission. Performance Measurement Initiatives. National Consensus Standards for Prevention and Care of Venous Thromboembolism (venous thromboembolism) [The Joint Commission web site]. Updated October 2008. http://www.jointcommission.org/PerformanceMeasurement/PerformanceMeasurement/venous thromboembolism.htm Accessed November 10, 2008